GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (OTCPK:CKDXF) » Definitions » Selling and Marketing Expense

CKDXF (Opthea) Selling and Marketing Expense : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Opthea Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Opthea's Selling and Marketing Expense for the six months ended in Jun. 2024 was $0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

Opthea Selling and Marketing Expense Historical Data

The historical data trend for Opthea's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Selling and Marketing Expense Chart

Opthea Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Opthea Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Opthea Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opthea Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Opthea's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (OTCPK:CKDXF) » Definitions » Selling and Marketing Expense
Comparable Companies
ASX:CUV ASX:PYCDA ASX:BOT ASX:IMM ASX:IMU ASX:RAC ASX:ALA ASX:DXB ASX:LTP ASX:OCC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
OPT:USA UKJ:Germany OPT:Australia
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Website
https://www.opthea.com
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.